RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $445 to $350.